These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


342 related items for PubMed ID: 15265000

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?
    Mackness M, Mackness B.
    Free Radic Biol Med; 2004 Nov 01; 37(9):1317-23. PubMed ID: 15454272
    [Abstract] [Full Text] [Related]

  • 4. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk.
    Mendonça MI, Dos Reis RP, Freitas AI, Pereira A, Sousa AC, Freitas S, Ornelas I, Freitas C, Brehm A, Araújo JJ.
    Rev Port Cardiol; 2010 Apr 01; 29(4):571-80. PubMed ID: 20734577
    [Abstract] [Full Text] [Related]

  • 5. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M, Karry R, Aviram M.
    Atherosclerosis; 2006 Jul 01; 187(1):74-81. PubMed ID: 16229851
    [Abstract] [Full Text] [Related]

  • 6. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, Castaldo M, Bitto A, Cinquegrani M, Saitta A.
    Curr Med Res Opin; 2005 May 01; 21(5):777-84. PubMed ID: 15969877
    [Abstract] [Full Text] [Related]

  • 7. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome.
    Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P.
    Arterioscler Thromb Vasc Biol; 2006 Jul 01; 26(7):1545-50. PubMed ID: 16627808
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes.
    Mastorikou M, Mackness M, Mackness B.
    Diabetes; 2006 Nov 01; 55(11):3099-103. PubMed ID: 17065348
    [Abstract] [Full Text] [Related]

  • 12. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K, Blazícek P, Waczulíková I, Zitnanová I, Duracková Z.
    Acta Biochim Pol; 2006 Nov 01; 53(4):783-7. PubMed ID: 17106515
    [Abstract] [Full Text] [Related]

  • 13. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects.
    Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, Zeljkovic A, Stefanovic A, Zunic G.
    Eur J Clin Invest; 2007 Sep 01; 37(9):715-23. PubMed ID: 17696961
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes.
    Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K.
    Metabolism; 2000 Nov 01; 49(11):1400-5. PubMed ID: 11092501
    [Abstract] [Full Text] [Related]

  • 16. Age-related paraoxonase activity changes in Turkish population.
    Saruhan E, Olgun A, Oztürk K, Akman S, Erbil MK.
    Ann N Y Acad Sci; 2007 Apr 01; 1100():218-22. PubMed ID: 17460182
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oxidative status and serum PON1 activity in beta-thalassemia minor.
    Selek S, Aslan M, Horoz M, Gur M, Erel O.
    Clin Biochem; 2007 Mar 01; 40(5-6):287-91. PubMed ID: 17296173
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.